Medication name: * Tri Bedoyecta Comparable patent medicine: Bedoyecta * Tri Active ingredient: hydroxocobalamin (vitamin B12), Thiamine (Vit B1), Pyridoxine (Vit B6) Presentation: Solution for Injection Concentration: 10.000 mg/100 mg/50 mg Extended-release tablets: No Lab: Grossman, S
The B12-carrier complex travels all the way down to the last section of the small intestine, the terminal ileum, where specific receptors absorb it into the bloodstream
Please enable Javascript in order to use PubChem website.
Key Takeaways Standard aod 9604 dosage: 300mcg/day subcutaneous, fasted AM Phase 2 clinical data showed 1mg/day as optimal most research protocols run 300500mcg 5mg vial + 2.5mL BAC water = 2,000mcg/mL
VK2735 Continuing on with the GLP-1 and GIP agonist theme, VK2735 from Viking Therapeutics is another potential candidate in the pipeline